Introduction
One of the early investigators who used ultrasound (US) energy to accelerate the fibrinolytic activity of thrombolytic drugs in vitro was Lauer.
1 Later, more in vitro studies have shown that US applications improved thrombolysis induced by thrombolytic agents (sonothrombolysis). The main goal in these in vitro studies was to deduce the optimum ultrasonic parameters to enhance sonothrombolysis (mostly frequency and intensity). 2 Another major goal was to test the best thrombolytic drug that enhances sonothrombolysis. 3, 4 The knowledge on sonothrombolysis gained in the in vitro studies was translated at a preclinical level by performing experiments in animals. Because in the in vitro experiments no side effects can be extracted, experimentation with animals was imperative. Still the main goal in the animal experiments was to extract the optimum ultrasonic parameters that maximize clot removal. 5 Additionally, different clot animal models were used which could test the various derived ultrasonic protocols. 6, 7 Progressively, US bubbles were employed which can possibly enhance the efficacy of sonothrombolysis. 5 When sufficient data were collected this research was translated into clinical trials. [8] [9] [10] The main goal in the clinical trials was to establish the safety and efficacy of sonothrombolysis. As was evident from these studies, the efficacy of this method was not very encouraging, therefore its deployment was not that impressive compared with the preclinical studies. Additionally, some side effects reported delayed the full deployment of this method.
This review is divided into 3 categories (in vitro, in vivo, and clinical) and provides a comprehensive compilation of protocols used during sonothrombolysis studies with or without thrombolytic drugs and/or microbubbles (MBs) since 1992. The aim of the review is to provide information regarding (1) the clot model used (human or animal for the in vitro studies and type of occlusion for the animal and clinical studies), (2) the US technique applied such as external or internal (catheter based) and focused or unfocused, (3) the use of flow system (only in vitro), (4) the temperature (only in vitro), (5) the type and concentration of thrombolytic drug used, (6) the treatment mode (US alone, drug alone, US + drug and US + drug + MBs), (7) the sonication parameters applied, such as frequency, intensity or acoustic power or negative pressure, pulse repetition frequency (PRF), duty factor (DF), and treatment time, (8) the evaluation method used to estimate study's outcome, (9) the effect of treatment on clot lysis, and (10) the main conclusions derived.
There is an absence in standardization about the necessary information collected from each study due to different methods/measuring units used by the investigators. For example, the output of US transducer is specified in different units (intensity, acoustic power, negative pressure, etc.), and the treatment's outcome is quantified by different evaluation methods such volume reduction, fibrin degradation products, lytic rate, recanalization rate, etc. Furthermore, in some cases experimental parameters like temperature, PRF and DF are not specified. This lack of standardization makes the comparison among various studies impossible. Additionally, although some impressive results were reported in the in vitro and in the animal studies, the outcomes of the clinical results were not that impressive. This could be attributed to the fact that in some studies, thermal effects were possibly reached, causing acceleration of sonothrombolysis, which, however, eventually produced severe side effects.
Materials and Methods
Published reports on sonothrombolysis that are available in PubMed (www.ncbi.nlm.nih.gov/pubmed) were collected. Information in several aspects of the protocols used in the studies examined were also extracted. In animal studies as well as in clinical trials, the following information was needed: clot model, thrombolytic drug and concentration, treatment mode, MBs administration, frequency, intensity or acoustic power or negative pressure, PRF, DF, treatment time, evaluation method, treatment's outcome, side effects, and main conclusions. In the in vitro compilation, the additional information needed was temperature. Table 1 lists the in vitro studies, Table 2 lists the in vivo studies, and Table 3 lists the clinical studies. The 3 tables include a comprehensive summary of all the issues involved in sonothrombolysis. These main issues are (1) the clot model used (human, animal, or in vitro), (2) type of occlusion (for animal and clinical models), (3) the coupling technique used (external or internal), (4) US modality (focused or unfocused), (5) the use of flow system (only for the in vitro studies), (6) indication of temperature (only for the in vitro studies), (7) the type of thrombolytic drug used, (8) concentration of thrombolytic drug used, (9) treatment mode (US alone, drug alone, US + drug and US + drug + MBs), (10) the applied frequency, (11) the applied intensity or acoustic power or negative pressure, (12) the applied PRF, (13) the applied DF, (14) the treatment time, (15) the evaluation method used to estimate the efficacy of sonothrombolysis, (16) the effect of treatment on clot lysis, and (17) the main conclusions derived.
Results
In the in vitro studies the most common clot model used was the human model (e.g., References 1-3, 12, and 13). In some cases the porcine model was used, 4, 48, 54, [56] [57] [58] the rabbit model, 46, 53 and the bovine. 45, 49 The intensity used ranged from .5 W/cm 2 to 193 W/cm 2 . The frequency used varied from 20 KHz to 2 MHz, whereas in most experiments the frequency used was about 1 MHz. The most typical thrombolytic drug used was the recombinant tissue plasminogen activator (rt-PA). In a few studies the urokinase (UK) was used. 21, 25, 32, 36 The concentration of the rt-PA varied from .1 to 100 µg/mL. In most of the studies the drug concentration is specified as µg/mL, and in some studies the IU/mL is specified. The treatment time used varied from .5 minutes to 720 minutes, whereas the majority of the studies used treatment time between 30 and 60 minutes. We have observed that in a few studies the clot temperature was not specified (e.g., References 36, 41, and 45) . Based on 1 study, 34 it is apparent that temperature plays an important role in sonothrombolysis and should be specified in all in vitro studies.
In the animal studies the most common clot models used were the rabbit model 5, 6, 48, [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [78] [79] [80] and the rat model. 1, 7, 63, 75 In the popular rabbit model the most commonly used artery was the femoral, followed by the middle cerebral artery (MCA) and the carotid. The frequency used varied from 20 kHz to 5.7 MHz, whereas in most experiments the frequency used was about 1 MHz. The most typical thrombolytic drug used was the rt-PA. In a few studies the streptokinase was used. 66, 70, 80 The concentration of the drug varied from .8 to 10 µg/mL. Clearly the doses used in animals were much lower than those used in the in vitro models. Most of the studies have evaluated the effect of US alone, thrombolytic drug alone, or the synergy of the 2 (US and drug). In most of the studies the intensity is specified, and in some studies the pressure is specified. The treatment time used varied from 2 minutes to 120 minutes, whereas the majority of the studies used treatment time of 60 minutes. Compared with the in vitro studies, in the animal studies, the additional parameter used was the inclusion of MBs. Several studies [71] [72] [73] [78] [79] [80] have shown that MBs may enhance the sonothrombolysis efficiency.
In all the human trials evaluated the clot model used was the MCA. The frequency used varied from 300 kHz to 4 MHz. In all the studies the thrombolytic drug used was the rt-PA. The concentration of the drug was .9 µg/ mL, which seems to be the safe dose used in humans. (continued on next page) (continued on next page) Abbreviations: Abib, abciximab immunobubbles; c.w., continuous wave; DF, duty factor; ELIP, echogenic liposomes; Epf., eptifibatide; Freq., frequency; FUS, focused ultrasound; HIFU, highintensity focused ultrasound; IA, intrarterial; IV, intravenous; MBs, microbubbles; MCA, middle cerebral artery; mt-PA, monteplase tissue plasminogen activator; n/s, not specified; Nsib, nonspecific immunobubbles; PRF, pulse repetition frequency; p.w., pulsed wave; Ref., references; rt-PA, recombinant tissue plasminogen activator; sICH; symptomatic intracranial hemorrhage; SK, streptokinase; TCD, transcranial Doppler; TCCD, transcranial color-coded duplex; Temp., temperature; TNK-tPA, tenecteplase tissue plasminogen activator; UK, urokinase; US, ultrasound. Abib, abciximab immunobubbles; c.w., continuous wave; DF, duty factor; ELIP, echogenic liposomes; Freq., frequency; HIFU, high-intensity focused ultrasound; IV, intravenous; MBs, microbubbles; MCA, middle cerebral artery; mt-PA, monteplase tissue plasminogen activator; Nsib, nonspecific immunobubbles; n/s, not specified; PRF, pulse repetition frequency; Ref., references; rt-PA, recombinant tissue plasminogen activator; SK, streptokinase; US, ultrasound. The treatment time used varied from 30 minutes to 10 minutes. In the animal and human studies, there was no need to specify the temperature. It is assumed that the specie of interest had the physiological temperature. In the human trials the modality used was the synergy of US and thrombolytic drugs. In some cases, 8, 84, 85, 88 the synergy with MBs was used.
Discussion
The current study compiled various aspects associated with the protocols examined (in vitro, in vivo, and clinical) that are used in sonothrombolysis. The review protocols are summarized in tables providing all necessary data in terms of clot model, treatment mode, sonication parameters, evaluation method, sonothrombolysis efficacy, and side effects. In addition, the main conclusions derived from each study are presented as well. This study could be useful for future researchers in this area because they can easily find the US parameters used during sonothrombolysis. Additionally, they can make comparison among the various protocols used and the animal models used.
Although the mechanisms behind sonothrombolysis are not very clear, it is evidenced that exposure to US increases the uptake and depth of penetration of thrombolytics into clots, 19 causes additional binding sites due to reversible disaggregation of fibrin fibers, 18 and increases the binding of thrombolytic agents to fibrin. 17 The influence of temperature on clot lysis was only investigated in vitro. In most of the experimental studies, the temperature during sonication was kept constant at 37°C, which sufficiently explains that clot lysis occurred through nonthermal mechanisms. In a few in vitro studies, the temperature at the target was not specified. Temperature played an important role on clot lysis because sonothrombolysis efficacy decreased at temperatures below the body baseline temperature of 37°C. 34 Therefore, it will be useful in the future, for all the in vitro studies to be conducted at 37°C.
In the animal studies the most common clot models used were the rabbit model (e.g., References 66-74). In the popular rabbit model, the most commonly used artery was the femoral, followed by the MCA and the carotid. The femoral model is used mostly because this artery is easily accessible. The MCA is widely used because of its relevance to brain stroke.
Different thrombolytic drugs such as UK, streptokinase, alteplase (rt-PA), and tenecteplase tissue plasminogen activator (TNK-tPA) in various concentrations have been investigated. Studies had shown that the synergy of US and any of these drugs could accelerate the thrombolytic activity of any thrombolytic used and that the extent of sonothrombolysis depended on the drug's concentration. 25, 59 The most common thrombolytic drug used by the researchers was rt-PA, because it is the only thrombolytic treatment approved for acute ischemic stroke. Although rt-PA was administered in various concentrations between .1 and 300 µg/mL, the majority of the above-mentioned studies were conducted using 3.15 µg/mL rt-PA, which is the average concentration of the drug detected in human blood.
The current review shows that the thrombolytic efficacy of drug alone is better than that of US alone. 23, 30, 35 Therefore, we assume that US energy as a stand-alone method for clot lysis is not effective and should be applied in synergy with thrombolytic drugs to enhance sonothrombolysis. However, a few studies 43, 44, 46 demonstrated that using US alone (in the absence of thrombolytic drug), could achieve almost complete clot lysis within seconds. Taking into consideration the very high level of acoustic power used in their studies as well as the temperature elevation at the target that was not specified in their results, we suspect that most likely the protocols applied were under the influence of thermal mechanisms of sonothrombolysis. This suspicion was supported by the results of many other researchers, 23, 30, 35 who exhibited reduced thrombolytic efficacy using US alone, although prolonged exposure times were used in their studies.
Some other studies focused their research on the effect of traveling versus standing acoustic waves on clot lysis, demonstrating that traveling acoustic waves enhanced sonothrombolysis significantly more than standing waves did. 11, 29 It is evident that researchers in this area should report whether standing waves are eliminated irrespective of the model used (in vitro, animal, or human).
It is well known that US frequency, as well as acoustic intensity, exerts a major effect on clot lysis. US frequencies ranged from 20 kHz to 5.0 MHz and intensities (either low or high) were employed for sonothrombolysis studies. A number of studies indicated that lower US frequencies (in the kilohertz range), are more efficient in sonothrombolysis over higher frequencies (in the MHz range) because they exhibited improved tissue penetration and greater acceleration in fibrinolysis. 16, 37, 38 Considering that some other studies showed that sonothrombolysis efficacy increases as the level of acoustic intensity increases, 24, 26, 28 it is reasonable to come to the conclusion that the thrombolytic efficacy of US waves is directly dependent on acoustic intensity and inversely dependent on frequency.
There was enough evidence from in vitro, 50 animal, 75 and clinical 84 studies indicating that the administration of MBs further enhanced the effect of US on enzymatic thrombolysis induced by thrombolytic agents. The findings of this review demonstrate that the boosting effect of MBs in clot dissolution correlated with the presence of cavitation mechanisms and most specifically with stable cavitation, which appeared to play a more important role in MB-mediated sonothrombolysis. 48, 51, 54 However, a study performed by Molina et al 88 showed that there is a safe limit on the administered dose of MBs, which should not be exceeded because it is associated with an increased risk of symptomatic intracranial hemorrhage (sICH) rate. Therefore, it is recommended that MBs should be administered in combination with rt-PA at low doses (1.4 mL) to enhance sonothrombolysis and avoid unnecessary adverse health effects, such as sICH. Animal studies, as well as clinical trials, have shown that the most common side effect of sonothrombolysis was sICH. Apart from the use of high dose of MBs, the application of low-frequency US might have increased the rate of sICH. The TRanscranial low-frequency sonothrombolysis in Brain Ischemia (TRUMBI) clinical trial, 87 which was designed to treat stroke patients with transcranial 300 kHz US plus rt-PA, was ended prematurely due to a significant increase in sICH rate. Since then, low-frequency US has not been available for therapeutic purposes in clinical trials. Additionally, our investigation showed that the risk of sICH rate increases with the concentration of thrombolytic drug 63 and the level of acoustic intensity. 64, 65 The effect of time is very critical on sonothrombolysis efficacy because early recanalization is the key to therapeutic success in the treatment of vascular thrombosis. In this review, the exposure times reported in the in vitro studies varied from .5 to 240 minutes. In the animal studies, the treatment times reported ranged from .5 to 120 minutes, whereas in the clinical trials, the continuous monitoring of the patients was between 30 and 120 minutes. Several studies 1, 33 showed that most of the clot mass was removed within the first 60 minutes of treatment and beyond that time the efficacy of thrombolytic treatment was decreased significantly. This phenomenon was possibly caused by the concentration of the thrombolytic drug in the blood after 60 minutes of treatment, which decreased dramatically, leading to a significant reduction on enzymatic fibrinolysis rate. Therefore, at least for in vitro or animal studies, 60 minutes of treatment must be a sufficient exposure time and should not be exceeded. The long treatment time required to remove clots using sonothrombolysis prohibits the use of this method for large occluded volumes. Perhaps, the physicians will attempt to treat critical clots, thus saving as much tissue as possible, given the long treatment time needed. To treat larger occluded volumes, a multi-element transducer technology is needed.
It is evident that the long treatment time needed (30-90 minutes) to dissolve a small amount of clot imposes a limitation of the wider use of sonothrombolysis. Because the time allowed to deliver the therapy is between 3 and 6 hours, the long treatment time needed limits the wide use of sonothrombolysis.
The analysis of the protocols used in the studies evaluated revealed that there is a lack of standardization in the recording of the ultrasonic dose. Some studies reported acoustic pressure, some other studies reported power, and some reported intensity.
The most common protocol used in clinical trials so far for the treatment of patients with acute ischemic stroke due to occlusion of the MCA was the continuous monitoring of the patients with high-frequency (2 MHz) low-intensity (<750 mW/cm 2 ) diagnostic transcranial US in combination with rt-PA. 83, 85 Using this protocol, higher recanalization rates were exhibited compared with those with rt-PA alone.
